24/7 Market News Snapshot 24 June, 2025 – Capricor Therapeutics Inc (NASDAQ:CAPR)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NASDAQ:CAPR) are discussed in this article.
Capricor Therapeutics Inc. (CAPR) has experienced a notable surge in its stock today, with shares opening at $7.90 and currently trading at $9.135, reflecting an impressive increase of approximately 18.95% from the previous close of $7.680. This rise can be attributed to a strong trading volume of 4.82 million shares, indicating heightened investor engagement. Analysts suggest that this significant breakout could mark a continuation pattern if the stock holds above the $9.00 resistance level. Investors are advised to monitor support levels around $8.00 to assess potential pullbacks, as the company’s momentum appears promising for future opportunities.

In a related development, Capricor Therapeutics, a leader in biotechnology focused on advanced therapies for rare diseases, has announced favorable regulatory updates concerning its lead product candidate, Deramiocel. This innovative therapy aims to address cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). The U.S. Food and Drug Administration (FDA) has determined that an Advisory Committee meeting is not necessary for this product at this stage, allowing Capricor to advance toward potential market approval.

The Biologics License Application (BLA) for Deramiocel is currently undergoing Priority Review, with the Prescription Drug User Fee Act (PDUFA) target action date set for August 31, 2025. CEO Linda Marbán, Ph.D., expressed confidence in the submission’s integrity, highlighting the favorable progress of regulatory milestones and the anticipated upcoming late-cycle review meeting.

Capricor showcased promising data from the HOPE-2 Open-Label Extension study, presented at the Parent Project Muscular Dystrophy (PPMD) Conference, which revealed that Deramiocel significantly preserves cardiac function over four years, underscoring the potential for sustained clinical benefits. DMD remains a severe genetic condition affecting muscle function, with limited treatment options available. Deramiocel, derived from allogeneic cardiosphere-derived cells, has received multiple designations from the FDA and European Medicines Agency (EMA) aimed at expediting its development, reaffirming Capricor’s commitment to innovative treatments for rare diseases.

Related news for (CAPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.